Home › Drug Resistant Epilepsy › NCT07145489

Infrared Photobiomodulation in Humans With Epilepsy

An Open Label Pilot Study of Infrared Photobiomodulation in Humans With Epilepsy

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Drug resistant epilepsy
* Age 18 or older
* Average seizure rate of at least 2 seizures per month
* Accurate seizure diary with at least 3 months recorded

Exclusion Criteria:

* Implanted intracranial neurostimulation device (DBS or RNS)
* Intracranial shunt
* Skin photosensitivity
* Cancer on scalp
* Taking any medication that can cause photosensitivity

About the study

Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.

What is being tested

• photobiomodulation (device)

Sponsor: Beth Israel Deaconess Medical Center · Participants: 13 · Started: Nov 25, 2025

Contact the study team

• Daniel Goldenholz, MD, PhD · Phone: 617-632-8930
• Daniel Goldenholz, MD PhD · Phone: 617-632-8930

Official record on ClinicalTrials.gov — NCT07145489

Locations in the U.S.

Conditions

• Drug Resistant Epilepsy
• Epilepsy
• Seizures

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.